Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nogapendekin alfa
- Development stage
- Approved
- Lead developer
- ImmunityBio
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravesical
01
Overview
Nogapendekin alfa is a human interleukin 15 (IL-15) superagonist, specifically an IL-15N72D variant, used as part of a fixed-dose combination with inbakicept (marketed as Anktiva) for the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. It is administered intravesically and always used alongside BCG. Nogapendekin alfa acts as an IL-15 receptor agonist, mimicking the biological actions of native IL-15 but with increased activity and longer half-life due to its N72D mutation. The drug stimulates proliferation and activation of natural killer cells, CD8+ T cells, and memory T cells without expanding immunosuppressive regulatory T cells. This immune activation leads to anti-tumor effects within the bladder wall[1][2][4][5][6][7].
- Brand names
- Anktiva
- Other names
- nogapendekin alfa inbakicepthuman IL-15N72D variant
02
Targets
IL2RB (IL-2 receptor beta chain)IL15RA (Interleukin-15 receptor subunit alpha)
Beyond the preview
Go deeper on nogapendekin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nogapendekin alfa.